| Bioactivity | Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC50s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca2+ influx and intracellular Ca2+ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice[1][2]. |
| Target | IC50: 0.84 nM (PAF-induced human platelet aggregation), 3.84 nM (PAF-induced rabbit platelet aggregation) |
| Name | Israpafant |
| CAS | 117279-73-9 |
| Formula | C28H29ClN4S |
| Molar Mass | 489.07 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Takehara S, et al. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors. Prostaglandins. 1990 Dec;40(6):571-83. [2]. Jan C R, Chao Y Y. Novel effect of Y-24180, a presumed specific platelet activation factor receptor antagonist, on Ca2+ levels and growth of human prostate cancer cells. Cellular signalling, 2004, 16(8): 959-965. |
Israpafant
CAS: 117279-73-9 F: C28H29ClN4S W: 489.07
Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.